Alkermes (NASDAQ: ALKS) posts preliminary 2025 revenue estimate

Rhea-AI Filing Summary

Alkermes plc filed a current report describing a new corporate presentation it will use at the J.P. Morgan Healthcare Conference. The presentation, furnished as Exhibit 99.1, includes the company’s estimated total revenues for the year ended December 31, 2025. These revenue figures are described as preliminary, unaudited and subject to change once Alkermes completes its review of its 2025 financial statements.

The company notes that the information in Items 2.02 and 7.01, and in Exhibit 99.1, is being furnished rather than filed, so it is not subject to certain Exchange Act liabilities or automatically incorporated into other securities law filings unless specifically referenced.

0001520262FalseAlkermes plc.00015202622026-01-122026-01-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): January 12, 2026

ALKERMES PUBLIC LIMITED COMPANY

(Exact name of registrant as specified in its charter)

Ireland		001-35299				98-1007018
(State or other jurisdiction		(Commission				(IRS Employer
of incorporation)		File Number)				Identification No.)
Connaught House, 1 Burlington Road
Dublin 4, Ireland D04 C5Y6
(Address of principal executive offices)

Registrant's telephone number, including area code: + 353-1-772-8000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐		Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐		Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐		Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐		Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Ordinary shares, $0.01 par value		ALKS		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Conditions.

On January 12, 2026, Alkermes plc (the “Company”) made available a copy of the corporate presentation to be displayed during its presentation at the J.P. Morgan Healthcare Conference on January 13, 2026, which includes the Company’s estimated total revenues for the year ended December 31, 2025, which are preliminary, unaudited and subject to change upon completion of the Company’s review of its financial statements for the year ended December 31, 2025. A copy of the presentation is furnished herewith as Exhibit 99.1.

Item 7.01 Regulation FD Disclosure.

The information in Item 2.02 above and in Exhibit 99.1 furnished herewith are incorporated in this Item 7.01 by reference.

The information contained in this Form 8-K, including in Items 2.02 and 7.01, and in Exhibit 99.1 furnished herewith, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

EXHIBIT INDEX

Exhibit No.		Description
99.1		Alkermes plc corporate presentation.
104		Cover page interactive data file (embedded within the Inline XBRL document).

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ALKERMES PLC
Date: January 12, 2026	By:		/s/ David J. Gaffin
			David J. Gaffin
			Secretary

3

FAQ

What did Alkermes (ALKS) disclose in this 8-K filing?

Alkermes disclosed that it made available a corporate presentation for its J.P. Morgan Healthcare Conference appearance, which includes estimated total revenues for the year ended December 31, 2025. These estimates are preliminary, unaudited and may change after the company completes its 2025 financial statement review.

What financial information does Alkermes (ALKS) provide about 2025?

The company indicates that the corporate presentation includes its estimated total revenues for the year ended December 31, 2025. Alkermes emphasizes that these revenue estimates are preliminary, unaudited and subject to change.

How is the Alkermes corporate presentation made available to investors?

Alkermes states that the corporate presentation being shown at the J.P. Morgan Healthcare Conference is made available and furnished as Exhibit 99.1 to this report, allowing investors to review the same materials used in the conference presentation.

Is the information in Alkermes’ presentation considered filed with the SEC?

The company specifies that the information in Items 2.02 and 7.01 and in Exhibit 99.1 is furnished, not filed, so it is not deemed filed under Section 18 of the Exchange Act and is not automatically incorporated into other securities filings unless explicitly referenced.

Which conference is referenced in this Alkermes (ALKS) disclosure?

The report notes that Alkermes will present at the J.P. Morgan Healthcare Conference on January 13, 2026, and that the corporate presentation for this event contains the company’s preliminary 2025 total revenue estimates.

What exhibits are included with this Alkermes 8-K?

The report lists Exhibit 99.1 as the Alkermes plc corporate presentation and Exhibit 104 as the cover page interactive data file embedded within the Inline XBRL document.